Press Release Exhibit 99.2 Late-breaking Dupixent® (dupilumab) data at ERS 2022 show consistent efficacy and safety profile for up to two years in children aged 6 to 11 years with moderate-to-severe asthma Paris and Tarrytown, N.Y. September 5, 2022. Results from a Phase 3 open-label extension trial demonstrated the efficacy and safety profile of Dupixent® (dupilumab) as a maintenance therapy when added to other asthma medications was consistent for up to two years in children aged 6 to 11 years with uncont ...

Sanofi SA (NASDAQ:SNY) Q2 2022 Earnings Conference Call July 28, 2022 8:30 AM ET Company Participants Eva Schaefer-Jansen - Head, IR Paul Hudson - CEO Jean-Baptiste de Chatillon - EVP & CFO Bill Sibold - EVP, Sanofi Genzyme and President, Sanofi North America John Reed - EVP & Global Head, Research & Development Thomas Triomphe - Head, Vaccines Olivier Charmeil - EVP, General Medicines Julie Van Ongevalle - EVP, Consumer Healthcare Conference Call Participants Wimal Kapadia - Sanford C. Bernstein Jo Walton ...

Driving growth with winning assets Business update Financial performance Outlook 2022 Appendices sanofi Driving growth with winning assets Business update Financial performance Outlook 2022 Appendices sonofi ● Q2 2022 Results Play to Win July 28, 2022 Driving growth with winning assets Business update Financial performance Outlook 2022 Appendices Forward-looking statements This document contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forwar ...

Exhibit 99.1 | | TABLE OF CONTENTS | | --- | --- | | 1. | CONDENSED HALF-YEAR CONSOLIDATED FINANCIAL STATEMENTS 2 | | | CONSOLIDATED BALANCE SHEETS – ASSETS 2 | | | CONSOLIDATED BALANCE SHEETS — SHAREHOLDERS' EQUITY AND LIABILITIES 3 | | | 4 CONSOLIDATED INCOME STATEMENTS | | | CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME 5 | | | CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY 6 | | | CONSOLIDATED STATEMENTS OF CASH FLOWS 9 | | | NOTES TO THE CONDENSED HALF-YEAR CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE ...

Excelling in strategy execution Business update Financial performance Outlook 2022 Appendices sanofi Excelling in strategy execution Business update Financial performance Outlook 2022 Appendices sonofi O Q1 2022 Results Play to Win April 28, 2022 Excelling in strategy execution Business update Financial performance Outlook 2022 Appendices Forward-looking statements This document contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forwardlooking ...

Sanofi SA (NASDAQ:SNY) Q1 2022 Earnings Conference Call April 28, 2022 8:30 AM ET Company Participants Eva Schaefer-Jansen - Head, IR Paul Hudson - CEO & Director John Reed - EVP & Global Head, Research & Development William Sibold - EVP, Specialty Care & President, Sanofi North America Thomas Triomphe - Head, Vaccines Olivier Charmeil - Head, General Medicines Julie Van Ongevalle - EVP, Consumer Healthcare Jean-Baptiste de Chatillon - EVP & CFO Brendan OÂ'Callaghan - EVP, Global Industrial Affairs Conferen ...

Exhibit 99.1 Information Statement DISTRIBUTION OF SHARES OF EUROAPI TO THE SHAREHOLDERS OF SANOFI This information statement is intended to provide shareholders of Sanofi ("Sanofi") in specified jurisdictions other than France (as set forth under "Notice to Prospective Shareholders of EUROAPI", the "Jurisdictions") with information relating to the proposed pro rata distribution of approximately 58% of the outstanding shares of the EUROAPI company ("EUROAPI" or the "Company") by Sanofi to its shareholders ( ...

sanofi ● Immunology Investor Event Cambridge, MA ● March 29, 2022 Forward-looking statements This document contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forwardlooking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, se ...

sanofi sanofi ● Tolebrutinib Investor Call ACTRIMS Forum 2022 February 24-26 | West Palm Beach, Florida ● February 25, 2022 Forward-looking statements This document contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forwardlooking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with r ...

. FORM 20-F 2021 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Or ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Or ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR ...